# Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

> **NCT06873763** · PHASE1,PHASE2 · RECRUITING · sponsor: **STCube, Inc.** · enrollment: 52 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)
- Recurrent Colorectal Cancer

## Interventions

- **DRUG:** Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab

## Key facts

- **NCT ID:** NCT06873763
- **Lead sponsor:** STCube, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2025-12
- **Final completion:** 2027-03
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873763, "Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06873763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*